The clinically available BET inhibitor, RVX208 (Apabetalone) showed promise in preclinical trials [26], where it reversed PA remodelling in various PAH rat models, potentially via modulation of proinflammatory, proproliferative and prosurvival pathways. Here, DNER is linked to pulmonary arterial hypertension.